Use of human papillomavirus vaccine in HIV-infected men for the prevention of anal dysplasia and cancer.

Abstract

There are two commercially available vaccines licensed worldwide for the prevention of cervical cancer and other human papillomavirus-associated cancers such as anal cancer. However, only two countries have implemented healthcare programs that include human papillomavirus vaccination for boys and men. Although most of the human papillomavirus-related cancers in the world are attributable to cervical cancer, in developed countries anal cancer accounts for a larger proportion of human papillomavirus-related cancers. Most cases of anal cancer occur in HIV-infected men who have sex with men. In this review, we discuss the burden of human papillomavirus-related cancers in men, the most plausible immune mechanism associated with the high efficacy of the human papillomavirus vaccine, and address key issues of vaccination for HIV-infected men. Finally, we review cost-effectiveness considerations for the use of the vaccine in boys and recent guidelines for vaccination in boys, with attention to HIV-infected men.

• Authors: Edward R Cachay, Wm Christopher Mathews
• Journal: AIDS reviews (AIDS Rev) 2014 Apr-Jun Vol. 16 Issue 2 Pg. 90-100 ISSN: 1698-6997 [Electronic] Spain
• PMID: 24818632 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Cancer Vaccines
• Papillomavirus Vaccines

Topics

• Anus Diseases (immunology, pathology, prevention & control)
• Cancer Vaccines (economics)
• Cost-Benefit Analysis
• HIV Seropositivity (immunology, pathology)
• Homosexuality, Male
• Humans
• Male
• Papillomavirus Infections (immunology, pathology, prevention & control)
• Papillomavirus Vaccines (economics)
• Secondary Prevention